Overview

Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study

Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
0
Participant gender:
All
Summary
Gliclazide has greater glucose lowering efficacy than glibenclamide among type 2 diabetes mellitus patients with minor haplotype (K23/A1369) at the KCNJ11/ABCC gene locations.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Khoo Teck Puat Hospital
Treatments:
Gliclazide
Glyburide
Criteria
Inclusion Criteria:

- Type 2 diabetes

- Age 21-65

- HbA1c >8.0% on two consecutive visits

Exclusion Criteria:

- Currently taking insulin at a regime more complex than basal insulin

- Not willing to perform self-blood glucose monitoring (SBGM)

- Renal impairment i.e. eGFR<50mls/min

- Pregnancy or unwilling to practice adequate contraception

- Taking other medications that may affect blood glucose e.g. systemic glucocorticoids.